Prospective multicenter non-randomized parallel-group comparative study to evaluate the efficacy of P-CAB/AMPC/MNZ 7 day triple therapy as first line eradication of CAM-resistant Helicobacter pylori: superiority study compared to P-CAB/AMPC/CAM, non-inferiority study compared to PPI/AMPC/MNZ, superiority study compared to PPI/AMPC/CAM
Not Applicable
- Conditions
- Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000022920
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 189
Inclusion Criteria
Not provided
Exclusion Criteria
Past history of taking eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. A patient with brain and spinal cord disease. A patient with infectious mononucleosis. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method